AllianceBernstein
RPRX

AllianceBernstein’s Repros Therapeutics Inc. RPRX Stock Holding History

AllianceBernstein’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-28,900
Closed -$248K – 3590
2015
Q1 		$248K Hold
28,900
– – ﹤0.01% 2743
2014
Q4 		$288K Sell
28,900
-5,200
-15% -$44.3K ﹤0.01% 2682
2014
Q3 		$338K Sell
34,100
-1,800
-5% -$26.7K ﹤0.01% 2622
2014
Q2 		$621K Hold
35,900
– – ﹤0.01% 2458
2014
Q1 		$637K Buy
35,900
+5,099
+17% +$98.7K ﹤0.01% 2350
2013
Q4 		$564K Sell
30,801
-621,648
-95% -$11.7M ﹤0.01% 2394
2013
Q3 		$17.5M Buy
652,449
+46,783
+8% +$1M 0.02% 688
2013
Q2 		$11.2M Buy
+605,666
New +$10.7M 0.01% 774

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DCM
Destrier Capital Management New York $144M AUM 7.28% 1-Year Est. Return

AllianceBernstein's RPRX Position: Q2 2015 in Review

AllianceBernstein sold out of Repros Therapeutics Inc. (RPRX) in Q2 2015, closing a stake of 28,900 shares — an estimated $248K sold.

AllianceBernstein first reported a position in RPRX in Q2 2013 and held it in 8 quarters. The position peaked at $17.5M in Q3 2013. 64 funds tracked by Wall St. Rank hold RPRX as of Q2 2015.

  • AllianceBernstein reported no remaining Repros Therapeutics Inc. position as of Q2 2015 after selling out during the quarter.
  • AllianceBernstein sold 28,900 Repros Therapeutics Inc. shares in Q2 2015, an estimated $248K.
  • AllianceBernstein first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 8 quarters.
  • AllianceBernstein's Repros Therapeutics Inc. position peaked at $17.5M in Q3 2013.
  • 64 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q2 2015.

Based on AllianceBernstein's 13F filing for Q2 2015, filed 14 Aug 2015.